Patent: 8,617,876
✉ Email this page to a colleague
Summary for Patent: 8,617,876
Title: | Rhodopsin gene conserved regions in a viral vector enhance expression |
Abstract: | The invention relates to gene suppression and replacement. In particular, the invention relates to enhanced expression of suppression agents for suppressing gene expression in a cell and in vivo and replacement nucleic acids that are not inhibited by the suppression agent. Regulatory elements are included in expression vectors to optimize expression of the suppression agent and/or replacement nucleic acid. |
Inventor(s): | Farrar; Gwyneth Jane (Co Dublin, IE), Millington-Ward; Sophia (Dublin, IE), Chadderton; Naomi (Dublin, IE), Palfi; Arpad (Co Wicklow, IE), O\'Reilly; Mary (Co Dublin, IE), Kenna; Paul (Dublin, IE), Humphries; Peter (Co Dublin, IE) |
Assignee: | The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth (Dublin, IE) N/A (N/A) |
Application Number: | 13/539,835 |
Patent Claims: | see list of patent claims |
Details for Patent 8,617,876
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2027-04-12 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2027-04-12 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2027-04-12 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |